Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest 10-K

View Latest 10-K

Stock Information


Nasdaq: DMPI




52 week Low/High

Day Low/High

Company Overview

DelMar Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new cancer therapies. Our lead product candidate, VAL-083, is a "first-in-class" small molecule DNA-targeting agent that is currently being evaluated in a biomarker-driven Phase 2 clinical trial for the treatment of Unmethylated MGMT refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. We are also exploring VAL-083 in a Phase 2 trial as a therapy for front-line Unmethylated MGMT GBM and other solid tumors, including ovarian cancer and pediatric CNS tumors.


DelMar Pharmaceuticals, Inc.
Suite 720 - 999 West Broadway
Vancouver, B.C., Canada V5Z 1K5

Investor Relations

T: (604) 629-5989

Transfer Agent

Island Stock Transfer
15500 Roosevelt Blvd
Suite 301
Clearwater, FL 33760
United States
T: 727-289-0010